Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 M^pro, Impairing Variants Replication In Vitro and In Vivo

• मुख्य लेखकों: Otávio Augusto Chaves (लेखक), Carolina Q. Sacramento (लेखक), André C. Ferreira (लेखक), Mayara Mattos (लेखक), Natalia Fintelman-Rodrigues (लेखक), Jairo R. Temerozo (लेखक), Leonardo Vazquez (लेखक), Douglas Pereira Pinto (लेखक), Gabriel P. E. da Silveira (लेखक), Laís Bastos da Fonseca (लेखक), Heliana Martins Pereira (लेखक), Aluana Santana Carlos (लेखक), Joana C. d'Avila (लेखक), João P. B. Viola (लेखक), Robson Q. Monteiro (लेखक), Patrícia T. Bozza (लेखक), Hugo Caire Castro- (लेखक), Thiago Moreno L. Souza (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: MDPI AG, 2021-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Atazanavir (ATV) has already been considered as a potential repurposing drug to 2019 coronavirus disease (COVID-19); however, there are controversial reports on its mechanism of action and effectiveness as anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Through the pre-clinical ch...